Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States-Reference-Cited by-同舟云学术

Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States

Published:2017-06 Issue:6 Volume:23 Page:653-664
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Oh Anna¹,Tran Dang M.²,McDowell Leann C.²,Keyvani Dor²,Barcelon Jay Andrew²,Merino Oscar²,Wilson Leslie²

Affiliation:

1. Department of Social and Behavioral Sciences, School of Nursing, University of California, San Francisco.

2. Department of Clinical Pharmacy, University of California, San Francisco.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States;Value in Health;2024-02

2. Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma;International Journal of Molecular Sciences;2024-02-01

3. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients;Melanoma Research;2024-01-05

4. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas;Frontiers in Oncology;2023-12-04

5. Review of pharmacoeconomic studies of melanoma treatment for the period 2018–2023;South Russian Journal of Therapeutic Practice;2023-09-25